Potential Target of CDK6 Signaling Pathway for Cancer Treatment.

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current drug targets Pub Date : 2024-01-01 DOI:10.2174/0113894501313781240627062206

Rajesh Basnet, Obed Boadi Amissah, Buddha Bahadur Basnet, Rongqi Huang, Yirong Sun, Jean de Dieu Habimana, Zhiyuan Li

{"title":"Potential Target of CDK6 Signaling Pathway for Cancer Treatment.","authors":"Rajesh Basnet, Obed Boadi Amissah, Buddha Bahadur Basnet, Rongqi Huang, Yirong Sun, Jean de Dieu Habimana, Zhiyuan Li","doi":"10.2174/0113894501313781240627062206","DOIUrl":null,"url":null,"abstract":"Background: Cancer involves uncontrolled cell growth due to genetic mutations. Tumors can form when CDK6, a gene essential for controlling cell growth, isn't working correctly. Researchers are investigating drugs that inhibit CDK6; some of them appear promising. Nevertheless, CDK6 is advantageous and harmful to cancer because it controls other cellular processes. By inhibiting CDK6 and CDK4, CDK4/6 inhibitors offer a novel therapeutic strategy that stops cell proliferation. The study investigates the function of CDK6 in cancer, the difficulties in targeting CDK6, and possible remedies.Objective: Scientists have developed drugs designed to block CDK6 and prevent it from altering other proteins. These drugs, also known as CDK6 inhibitors, help treat cancer. Finding the best drugs for CDK6 is still tricky, though. The drugs' selectivity, potency, and cost are some difficulties. These factors depend on CDK6's structure and interactions with other proteins. The structure of CDK6 and how it influences its function and regulation are explained in this review. It also describes CDK6's function in cancer and its interaction with other molecules and proteins, which is crucial for cell division. This review also discusses the present and upcoming therapies that target CDK6, as well as how CDK6 interacts with drugs that block it.Conclusion: This review presents the structure, current research, and overview of CDK6. It also reviews the role of CDK6 in cancer, function, and regulation. Additionally, it explores its role in cancer signaling networks and its interaction with CDK6 inhibitors. Lastly, it discusses the current status and prospects of therapies targeting CDK6.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"724-739"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113894501313781240627062206","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cancer involves uncontrolled cell growth due to genetic mutations. Tumors can form when CDK6, a gene essential for controlling cell growth, isn't working correctly. Researchers are investigating drugs that inhibit CDK6; some of them appear promising. Nevertheless, CDK6 is advantageous and harmful to cancer because it controls other cellular processes. By inhibiting CDK6 and CDK4, CDK4/6 inhibitors offer a novel therapeutic strategy that stops cell proliferation. The study investigates the function of CDK6 in cancer, the difficulties in targeting CDK6, and possible remedies.

Objective: Scientists have developed drugs designed to block CDK6 and prevent it from altering other proteins. These drugs, also known as CDK6 inhibitors, help treat cancer. Finding the best drugs for CDK6 is still tricky, though. The drugs' selectivity, potency, and cost are some difficulties. These factors depend on CDK6's structure and interactions with other proteins. The structure of CDK6 and how it influences its function and regulation are explained in this review. It also describes CDK6's function in cancer and its interaction with other molecules and proteins, which is crucial for cell division. This review also discusses the present and upcoming therapies that target CDK6, as well as how CDK6 interacts with drugs that block it.

Conclusion: This review presents the structure, current research, and overview of CDK6. It also reviews the role of CDK6 in cancer, function, and regulation. Additionally, it explores its role in cancer signaling networks and its interaction with CDK6 inhibitors. Lastly, it discusses the current status and prospects of therapies targeting CDK6.

查看原文本刊更多论文

CDK6 信号通路治疗癌症的潜在靶点。

背景：癌症是由于基因突变导致的细胞生长失控。CDK6是一种控制细胞生长的重要基因，如果它不能正常工作，就会形成肿瘤。研究人员正在研究抑制 CDK6 的药物，其中一些似乎很有前景。不过，CDK6 对癌症有利也有弊，因为它控制着其他细胞过程。通过抑制 CDK6 和 CDK4，CDK4/6 抑制剂提供了一种阻止细胞增殖的新型治疗策略。本研究调查了 CDK6 在癌症中的功能、靶向 CDK6 的困难以及可能的补救措施：科学家们已经开发出旨在阻断 CDK6 并防止其改变其他蛋白质的药物。这些药物也称为 CDK6 抑制剂，有助于治疗癌症。不过，找到治疗 CDK6 的最佳药物仍很棘手。药物的选择性、效力和成本都是一些难题。这些因素取决于 CDK6 的结构以及与其他蛋白质的相互作用。本综述将解释 CDK6 的结构及其如何影响其功能和调控。本综述还介绍了 CDK6 在癌症中的功能及其与其他分子和蛋白质的相互作用，这对细胞分裂至关重要。此外，本综述还介绍了 CDK6 与阻断 CDK6 的药物之间的相互作用，以及目前和未来针对 CDK6 的治疗方法：本综述介绍了 CDK6 的结构、当前研究和概述。结论：本综述介绍了 CDK6 的结构、研究现状和概述，还回顾了 CDK6 在癌症中的作用、功能和调节。此外，它还探讨了 CDK6 在癌症信号网络中的作用及其与 CDK6 抑制剂的相互作用。最后，它讨论了 CDK6 靶向疗法的现状和前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug targets 医学-药学

CiteScore

6.20

自引率

0.00%

发文量

127

审稿时长

3-8 weeks

期刊介绍： Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.